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ABSTRACT
Our aging population increasingly suffers from multiple chronic
diseases simultaneously, necessitating the comprehensive treat-
ment of these conditions. Finding the optimal set of drugs
and interventions for a combinatorial set of diseases is a
combinatorial pattern exploration problem. Association rule
mining is a popular tool for such problems, but the require-
ment of health care for finding causal, rather than asso-
ciative, patterns renders association rule mining unsuitable.
One of the purpose of this study was to apply SSC guide-
line recommendations to EHR data for patients with severe
sepsis or septic shock and determine guideline compliance
as well as its impact on inpatient mortality and sepsis com-
plications. Propensity Score Matching in conjuction with
Bootstrap Simulation were used to match patients with and
without exposure to the SCC recommendations. Findings
showed that EHR data could be used to estimate compli-
ance with SCC recommendations as well as the effect of
compliance on outcomes. Further, we propose a novel frame-
work based on the Rubin-Neyman causal model for extract-
ing causal rules from observational data, correcting for a
number of common biases. Specifically, given a set of in-
terventions and a set of items that define subpopulations
(e.g., diseases), we wish to find all subpopulations in which
effective intervention combinations exist and in each such
subpopulation, we wish to find all intervention combina-
tions such that dropping any intervention from this com-
bination will reduce the efficacy of the treatment. A key
aspect of our framework is the concept of closed interven-
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tion sets which extend the concept of quantifying the effect
of a single intervention to a set of concurrent interventions.
Closed intervention sets also allow for a pruning strategy
that is strictly more efficient than the traditional pruning
strategy used by the Apriori algorithm. To implement our
ideas, we introduce and compare five methods of estimating
causal effect from observational data and rigorously evalu-
ate them on synthetic data to mathematically prove (when
possible) why they work. We also evaluated our causal rule
mining framework on the Electronic Health Records (EHR)
data of a large cohort of patients from Mayo Clinic and
showed that the patterns we extracted are sufficiently rich
to explain the controversial findings in the medical literature
regarding the effect of a class of cholesterol drugs on Type-II
Diabetes Mellitus (T2DM).
Keywords
Causal Inference, Confounding, Counterfactual Estimation.
1. RELATEDWORK
Causation has received substantial research interest in many
areas. In computer science, Pearl [5] and Rosenbaum[6]
laid the foundation for causal inference, upon which several
fields, cognitive science, econometrics, epidemiology, philos-
ophy and statistics have built their respective methodologies
[7, 8, 9].
At the center of causation is a causal model. Arguably,
one of the earliest and popular models is the Rubin-Neyman
causal model [3]. Under this model X causes Y , if X occusr
before Y ; and without X, Y would be different. Beside
the Rubin-Neyman model, there are several other causal
models, including the Granger causality [10] for time se-
ries, Bayes Networks [11], Structural Equation Modeling [8],
causal graphical models [12], and more generally, probabilis-
tic graphical models [13]. In our work, we use the potential
outcome framework from the Rubin-Neyman model and we
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use causal graphical models to identify and correct for bi-
ases.
Causal graphical models are tools to visualize causal re-
lationships among variables. Nodes of the causal graph are
variables and edges are causal relationships. Most methods
assume that the causal graph structure is a priori given, how-
ever, methods have been proposed for discovering the struc-
ture of the causal graph [14, 15]. In our work, the structure
is partially given: we know the relationships among groups
of variables, however we have to assign each variable to the
correct group based on data.
Knowing the correct graph structure is important, because
substructures in the graph are suggestive of sources of bias.
To correct for biases, we are looking for specific substruc-
tures. For example, causal chains can be sources of overcor-
rection bias and ”V”-shaped structures can be indicative of
confounding or endogenous selection bias [9]. Many other
interesting substructures have been studied [16, 17, 18]. In
our work, we consider three fundamental such structures:
direct causal effect, indirect causal effect and confounding.
Of these, confounding is the most severe and received the
most research interest.
Numerous methods exist to handle confounding, which
includes propensity score matching (PSM) [19], structural
marginal models [9] and g-estimation [8]. The latter two
extend PSM for various situations, for example, for time-
varying interventions [9].
Propensity score matching is used to estimate the effect
of an intervention on an outcome. The propensity score is
the propensity (probability) of a patient receiving the inter-
vention given his baseline characteristics and the propensity
score is used to create a new population that is free of con-
founding. Many PSM techniques exist and they typically
differ in how they use the propensity score to create this
new population [20, 21, 22, 23].
Applications of causal modeling is not exclusive to social
and life sciences. In data mining, Lambert et al. [24] in-
vestigated the causal effect of new features on click through
rates and Chan et al. [25] used doubly robust estimation
techniquest to determine the efficacy of display advertise-
ments.
Even extending association rules mining to causal rule
mining has been attempted before [26, 27, 28]. Li et al.
[26] used odds ratio to identify causal patterns and later ex-
tended their technique [28] to handle large data set. Their
technique, however, is not rooted in a causal model and
hence offers no protection against computing systematically
biased estimates. In their proposed causal decision trees
[29], they used the potential outcome framework, but still
have not addressed correction for various biases, including
confounding.
2. SIMPLE CAUSAL RULEMINING IN IR-
REGULAR TIME-SERIES DATA
2.1 Introduction
According to the Center for Disease Control and Preven-
tion, the incidence of sepsis or septicemia has doubled from
2000 through 2008, and hospitalizations have increased by
70% for these diagnoses1. In addition, severe sepsis and
shock have higher mortality rates than other sepsis diag-
noses, accounting for an estimated mortality between 18%
and 40%. During the first 30 days of hospitalization, mor-
tality can range from 10% to 50% depending on the patients
risk factors. Patients with severe sepsis or septic shock are
sicker, have longer hospital stays, are more frequently dis-
charged to other short-term hospital or long-term care insti-
tutions, and represent the most expensive hospital condition
treated in 20112.
The use of evidence-based practice (EBP) guidelines, such
as the Surviving Sepsis Campaign (SSC), could lead to an
earlier diagnosis, and consequently, earlier treatment. How-
ever, these guidelines have not been widely incorporated
into clinical practice. The SSC is a compilation of interna-
tional recommendations for the management of severe sep-
sis and shock. Many of these recommendations are inter-
ventions to prevent further system deterioration during and
after diagnosis. Even when the presence of sepsis or progres-
sion to sepsis is suspected early in the course of treatment,
timely implementation of adequate treatment management
and guideline compliance are still a challenge. Therefore,
the effectiveness of the guideline in preventing clinical com-
plications for this population is still unclear to clinicians and
researchers alike.
The majority of studies have focused on early detection
and prevention of sepsis and little is known about the com-
pliance rate to SSC and the impact of compliance on the pre-
vention of sepsis-related complications. Further, the mea-
surement of adherence to individual SSC recommendations
rather than the entire SSC is, to our knowledge, limited. The
majority of studies have used traditional randomized control
trials with analytic techniques such as regression modeling to
adjust for risk factors known from previous research. Data-
driven methodologies, such as data mining techniques and
machine learning, have the potential to identify new insights
from electronic health records (EHRs) that can strengthen
existing EBP guidelines.
The national mandate for all health professionals to imple-
ment interoperable EHRs by 2015 provides an opportunity
for the reuse of potentially large amounts of EHR data to ad-
dress new research questions that explore patterns of patient
characteristics, evidence-based guideline interventions, and
improvement in health. Furthermore, expanding the range
of variables documented in EHRs to include team-based as-
sessment and intervention data can increase our understand-
ing of the compliance with EBP guidelines and the influence
of these guidelines on patient outcomes. In the absence of
such data elements, adherence to guidelines can only be in-
ferred; it cannot be directly observed.
In this section, we present a methodology for using EHR
data to estimate the compliance with the SSC guideline rec-
ommendations and also estimate the effect of the individ-
ual recommendations in the guideline on the prevention of
in-hospital mortality and sepsis-related complications in pa-
tients with severe sepsis and septic shock.
2.2 Methods
Data from the EHR of a health system in the Midwest
was transferred to a clinical data repository (CDR) at the
University of Minnesota which is funded through a Clini-
cal Translational Science Award. After IRB approval, de-
identified data for all adult patients hospitalized between
1/1/09 to 12/31/11 with a severe sepsis or shock diagnosis
was obtained for this study.
2.2.1 Data and cohort selection
The sample included 186 adult patients age 18 years or
older with an ICD-9 diagnosis code of severe sepsis or shock
(995.92 and 785.5*) identified from billing data. Since 785.*
codes corresponding to shock can capture patients without
sepsis, patients without severe sepsis or septic shock, and pa-
tients who did not receive antibiotics were excluded. These
exclusions aimed to capture only those patients who had se-
vere sepsis and septic shock, and were treated for that clin-
ical condition. The final sample consisted of 177 patients.
2.2.2 Variables of interest
Fifteen predictor variables (baseline characteristics) were
collected. These include sociodemographics and health dis-
parities data: age, gender, race, ethnicity, and payer (Medi-
caid represents low income); laboratory results: lactate and
white blood cells count (WBC); vital signs: heart rate (HR),
respiratory rate (RR), temperature (Temp), mean arterial
blood pressure (MAP); and diagnoses for respiratory, car-
diovascular, cerebrovascular, and kidney-related comorbid
conditions. ICD-9 codes for comorbid conditions were se-
lected according to evidence in the literature . Comorbidities
were aggregated from the patientaˆA˘Z´s prior problem list to
detect preexisting (upon admission) respiratory, cardiovas-
cular, cerebrovascular, and kidney problems. Each category
was treated as yes/no if any of the ICD-9 codes in that cat-
egory were present.
The outcomes of interest were inhospital mortality and de-
velopment of new complications (respiratory, cardiovascular,
cerebrovascular, and kidney) during the hospital encounter.
New complications were determined as the presence of ICD-
9 codes on the patients billing data that did not exist at the
time of the admission.
2.2.3 Study design
This study aimed to analyze compliance with the SSC
guideline recommendations in patients with severe sepsis or
septic shock. Therefore, the baseline (TimeZero) was de-
fined as the onset of sepsis and the patients were under ob-
servation until discharged. Unfortunately, the timestamp
for the diagnoses is dated back to the time of admission;
hence the onset of sepsis needs to be estimated. The onset
time for sepsis was defined as the earliest time during a hos-
pital encounter when the patient meets at least two of the
following six criteria: MAP < 65, HR >100, RR >20, tem-
perature < 95 or >100.94, WBC < 4 or > 12, and lactate >
2.0. The onset time was established based on current clinical
practice and literature on sepsis5. The earliest time when
two or more of these aforementioned conditions were met,
a TimeZero flag was added to the time of first occurrence
of that abnormality, and the timing of the SSC compliance
commenced.
2.2.4 Guideline compliance
SSC guideline recommendations were translated into a
readily computable set of rules. These rules have condi-
tions related to an observation (e.g. MAP < 65 Hgmm) and
an intervention to administer (e.g. give vasopressors) if the
patient meets the condition of the rule. The SSC guideline
was transformed into 15 rules in a computational format,
one for each recommendation in the SSC guideline recom-
mendations, and each rule was evaluated for each patient
(see Figure 1). After each rule is an abbreviated name sub-
sequently used in this paper.
Figure 1: SSC rules for measuring guideline compli-
ances
We call the treatment of a patient compliant (exposed) for
a specific recommendation, if the patient meets the condi-
tion of the corresponding rule any time after TimeZero and
the required intervention was administered; the treatment
is non-compliant (unexposed) if the patient meets the con-
dition of the corresponding rule after TimeZero, but the in-
tervention was not administered (any time after TimeZero);
and the recommendtion is not applicable to a treatment if
the patient does not meet the condition of the corresponding
rule. In estimating compliance (as a metric) with a specific
recommendation, we simply measure the number of compli-
ant encounters to which the recommendation is applicable.
In this phase of the study, the time when a recommendation
was administered was not incorporated in the analysis.
We also estimate the effect of the recommendation on the
outcomes. We call a patient exposed to a recommendation,
if the recommendation is applicable to the patient and the
corresponding intervention was administered to the patient.
We call a patient unexposed to a recommendation if the rec-
ommendation is applicable but was not applied (the treat-
ment was non-compliant). The incidence fraction in exposed
patients with respect to an outcome is the fraction of pa-
tients with the outcome among the exposed patients. The
incidence fraction of the unexposed patients can be defined
analogously. We define the effect of the recommendation
on an outcome as the difference in the incidence fractions
between the unexposed and exposed patients. The recom-
mendation is beneficial (protective against an outcome) if
the effect is positive, namely, the incidence faction in the
unexposed is higher than the incidence fraction in the unex-
posed patients.
2.2.5 Data quality
Included variables were assessed for data quality regard-
ing accuracy and completeness based on the literature and
domain knowledge. Constraints were determined for plausi-
ble values, e.g., a CVP reading could not be greater than 50.
Values outside of constraints were recoded as missing values.
Any observation that took place before the estimated onset
of sepsis (TimeZero) was considered a baseline observation.
Simple mean imputation was the method of choice for im-
puting missing values. Imputation was necessary for lactate
(7.7%), temperature (3%), and WBC (3%). There was no
missing data for the other variables and for the outcomes
of interest. Central venous pressure was not included as a
baseline characteristic due to the high number of missing
values (54%).
2.2.6 Propensity score matching
Patients who received SSC recommendations may be in
worse health than patient who did not receive SSC rec-
ommendations. For example, patients whose lactate was
measured may have more apparent (and possibly advanced)
sepsis than patients whose lactate was not measured. To
compensate for such disparities, propensity score matching
(PSM) was employed. The goal of PSM is to balance the
data set in terms of the covariates between patients exposed
and unexposed to the SSC guideline recommendations. This
is achieved by matching exposed patients with unexposed
patients on their propensity (probability) of receiving the
recommendations. This ensures that at TimeZero, pairs of
patients, one exposed and one unexposed, are at the same
state of health and they only differs in their exposure to the
recommendation. PSM is a popular technique for estimating
treatment effects.
To compute the propensity of patients to receive treat-
ment, a logistic regression model was used, where the de-
pendent variable is exposure to the recommendation and
the independent variables are the covariates. The linear
prediction (propensity score) of this model was computed
for every patient. A new (matched) population was created
from pairs of exposed and unexposed patients with match-
ing propensity scores. Two scores match if they differ by no
more than a certain caliper (.1 in our study). The effect of
the recommendation was estimated by comparing the inci-
dent fraction among the exposed and unexposed patients in
the matched population.
2.2.7 PSM nested inside bootstrapping simulation
In order to incorporate the effect of additional sources of
variability arising due to estimation in the propensity score
model and variability in the propensity score matched sam-
ple, 500 bootstrap samples were drawn from the original
sample. In each of these bootstrap iterations, the propensity
score model was estimated using the above caliper matching
techniques and the effect of the recommendation was com-
puted with respect to all outcomes. In recent years, boot-
strap simulation has been widely employed in conjunction
with PSM to better handle bias and confounding variables.
For each recommendation and outcome, the 500 bootstrap
iterations result in 500 estimates of the effect (of the recom-
mendation on the outcome), approximating the sampling
distribution of the effect.
2.3 Results
Table 1 shows the baseline characteristics of the study
population. Results are reported as total count for categor-
ical variables, and mean with inter-quartile (25% to 75%)
range for continuous variables. As shown in Table 1, the
majority of patients were male, Caucasian, and had Medi-
caid as the payer. Before the onset of sepsis, Cardiovascular
comorbidities (56.4%) were common, the mean HR (101.3)
was slightly above the normal, as well as lactate (2.8), and
WBC (15.8). The mean length of stay for the sample was 15
days, ranging from less than 24 hours to 6 months. TimeZero
was within the first 24 hours of admission, and patients at
that time were primarily (86.4%) in the emergency depart-
ment.
Feature Mean
Total Number of Patients 177
Average Age 61
Gender(Male) 102
Race(Caucasian) 97
Ethnicity(Latino) 11
Payer(Medicaid) 102
White Blood cell 15.8
Lactate 28
Mean blood Pressure 73.9
Temperature 98.4
Heart Rate 101.3
Respiratory Rate 20.6
Cardiovascular 100
Cerebrovascular 66
Respiratory 69
Kidney 62
Table 1: Demographics statistics of patient popula-
tion
In Figure 2, the effects of various rule-combination pairs
are depicted. An effect is defined as the difference in the
mean rate of progression to complications between the ex-
posed and unexposed groups. Since we used bootstrap simu-
lation, for each rule-complication pair, 500 replications were
performed resulting in a sampling distribution for the ef-
fect. Sampling distribution for each rule-association pair is
presented as boxplots. The boxplots represent the statis-
tic measured, i.e. in this study, the differential impact of
a recommendation on mortality between the exposed and
unexposed population. When this statistic is 0, the recom-
mendation has no effect. If the recommendation is greater
than 0, it means that the recommendation is protective for
that specific condition; and if the recommendation is below
0, the recommendation may even increase the risk for the
outcome for that specific condition.
The panes (groups of boxplots) correspond to the compli-
cations and the boxes within each pane correspond to the
recommendation (rule). For example, the effect of the Ven-
tilator rule (Recommendation 15: patients in respiratory
distress should be put on ventilator) on mortality (Death) is
shown in the rightmost box (Ventilator) in the bottom-most
pane (Death). Since all effects in the boxplot are above 0,
namely the number of observed complications in the unex-
posed group is higher than in the exposed, compliance with
the Ventilator rule reduces the number of deaths. Therefore,
the corresponding recommendation is beneficial to protect
patients from Death (mortality). In Table 3, we present the
95% Confidence Intervals for various rule-outcome pairs.
95% Confidence intervals for various rule-outcome pairs.
Figure 2: Box-plots of the mean difference between
groups (unexposed - exposed) to the guideline rec-
ommendations and each of the outcomes of interest.
To further ensure the validity of the results, we examine the
propensity score distribution in the exposed and unexposed
group. As an example, Figure 3 illustrates the propensity
score distribution for a randomly selected bootstrap iter-
ation to measure the effect of Ventilator on Death. The
horizontal axis represents the propensity score, which is the
probability of receiving the interventions, and the vertical
axis represents the density distribution, namely the propor-
tion of patients in each group with a particular propensity
for being put on Ventilator. Figure 3 shows substantial
overlap between the propensity scores in the exposed and
unexposed group. The propensity score overlap represents
the distribution; the predictor Ventilator across the exposed
and unexposed populations regarding the outcome Death;
the balance was successful when the propensity score was
applied for this population. Other rule-complication pairs
exhibit similar propensity score distribution.
3. CONCLUSION
The overall purpose of this study was to use EHR data to
determine compliance with the Surviving Sepsis Campaign
Figure 3: Distribution of the propensity scores be-
tween exposed and unexposed groups for the out-
come Death when patients and the SSC recommen-
dation was Ventilator..
(SSC) guideline and measure its impact on inpatient mor-
tality and sepsis complications in patients with severe sep-
sis and septic shock. Results showed that compliance with
many of the recommendations was> 95% for MAP and CVP
with fluid resuscitation given for low readings. Other high
compliance (greater than 80%) recommendations were: in-
sulin given for high blood glucose and evaluating respiratory
distress. The recommendations with the lowest compliance
(< 30%) were: vasopressor or albumin for continuing low
MAP or CVP readings. This may be due to a study de-
sign artifact, where the rule only considered interventions
initiated after TimeZero (estimated onset of sepsis) while
the fluid resuscitation may have taken place earlier. Al-
ternatively, the apparently poor compliance could also be
explained with issues related to the coding of fluids: during
data validation, we found that it was difficult to track fluids.
Our study also demonstrates that retrospective EHR data
can be used to evaluate the effect of compliance with guide-
line recommendations on outcomes. We found a number
of SSC recommendations that were significantly protective
against more than one complication: Ventilator was protec-
tive against Cardiovascular and Respiratory complications
as well as Death; use of Vasopressors was protective for Res-
piratory complications.
Other recommendations, BCulture, Antibiotic, Vasopres-
sor, Lactate, CVP, and RespDistress, showed results less
consistent with our expectation. For instance, Vasopressor
used to treat low MAP, appears to increase cerebrovascular
complications. While this finding is not statistically signif-
icant, it may be congruent with the fact that small brain
vessels are very sensitive to changes in blood pressure. Low
MAP can cause oxygen deprivation, and consequently brain
damage.
Ventilator, Vasopressor, and BGlucose showed protective
effects against Respiratory complications. The SSC guide-
line recommends the implementation of ventilator therapy
as soon as any change in respiratory status is noticed. This
intervention aims to protect the patient against further sys-
tem stress, restore hypoxia, help with perfusion across the
main respiratory-cardio vessels, and decrease release of tox-
ins due to respiratory efforts.
Our study is a proof-of-concept study demonstrating that
EHR data can be used to estimate the effect of guideline
recommendations. However, for several combinations of rec-
ommendations and outcomes, the effect was not significant.
We believe that the reason is that guidelines represent work-
flows and the effect of the workflow goes beyond the effects of
the individual guideline recommendations. For example, by
considering the recommendations outside the context of the
workflow, we may ignore whether the intervention addressed
the condition that triggered its administration. If low MAP
triggered the administration of vasopressors, without consid-
ering the workflow, we do not know whether MAP returned
to the normal levels thereafter. Thus we cannot equate an
adverse outcome with the failure of the guideline, it may be
the result of the insufficiency of the intervention. Moving
forward, we are going to model the workflows behind the
guidelines and apply the same principles that we developed
in this work to estimate the effect of the entire workflow.
This phase of our study did not address the timing of
recommendations nor the time prior to TimeZero. For this
analysis, guideline compliance was considered only after Time-
Zero (the estimated onset), since compliance with SSC is
only necessary in the presence of suspected or confirmed sep-
sis. There is no reason to suspect sepsis before TimeZero.
However, some interventions may have started earlier, with-
out respect to sepsis. For example, 100% of the patients
in this sample had antibiotics (potentially preventive antibi-
otics), but only 99 (55%) patients received it after TimeZero.
The EHR does not provide date and time for certain ICD-
9 diagnoses. During a hospital stay, all new diagnoses are
recorded with the admission date. We know whether a diag-
nosis was present on admission or not, thus we know whether
it is a preexisting or new condition, but do not know pre-
cisely when the patient developed this condition during the
hospitalization. For this reason, we are unable to detect
whether the SSC guideline was applied before or after a com-
plication occurred, thus we may underestimate the beneficial
effect of some of the recommendations. For example, high
levels of lactate is highly related to hypoxia and pulmonary
damage. If these patients were checked for lactate after pul-
monary distress, we would consider the treatment compliant
with the Lactate recommendation, but we would not know
that the respiratory distress was already present at the time
of the lactate measurement and we would incorrectly count
it as a complication that the guideline failed to prevent.
4. COMPLEX CAUSAL RULE MINING IN
IRREGULAR TIME-SERIES DATA
4.1 Introduction
Effective management of human health remains a major
societal challenge as evidenced by the rapid growth in the
number of patients with multiple chronic conditions. Type-
II Diabetes Mellitus (T2DM), one of those conditions, af-
fects 25.6 million (11.3%) Americans of age 20 or older and
is the seventh leading cause of death in the United States [1].
Effective treatment of T2DM is frequently complicated by
diseases comorbid to T2DM, such as high blood pressure,
high cholesterol, and abdominal obesity. Currently, these
diseases are treated in isolation, which leads to wasteful du-
plicate treatments and suboptimal outcomes. The recent
rise in the number of patients with multiple chronic condi-
tions necessitates comprehensive treatment of these condi-
tions to reduce medical waste and improve outcomes.
Finding optimal treatment for patients who suffer from
multiple associated diseases, each of which can have mul-
tiple available treatments is a complex problem. We could
simply use techniques based on association, but a reasonable
algorithm would likely find that the use of a drug is associ-
ated with some unfavorable outcome. This does not mean
that the drug is harmful; in fact in many cases, it simply
means that patients who take the drug are sicker than those
who do not and thus they have a higher chance of the unfa-
vorable outcome. What we really wish to know is whether
a treatment causes an unfavorable outcome, as opposed to
being merely associated with it.
The difficulty in quantifying the effect of interventions on
outcomes stems from subtle biases. Suppose we wish to
quantify the effect of a cholesterol-lowering agent, statin, on
diabetes. We could simply compare the proportion of dia-
betic patients in the subpopulation that takes statin and the
subpopulation that does not and estimate the effect of statin
as the difference between the two proportions. This method
would give the correct answer only if the statin-taking and
non-statin-taking patients are identical in all respects that
influence the diabetes outcome. We refer to this situation
as treated and untreated patients being comparable. Unfor-
tunately, statin taking patients are not comparable to non-
statin-taking patients, because they take statin to treat high
cholesterol, which by and in itself increases the risk of dia-
betes. High cholesterol confounds the effect of statin. Many
difference sources of bias exist, confounding is just one of the
many. In this manuscript, we are going to address several
different sources of bias, including confounding.
Techniques to address such biases in causal effect estima-
tion exist. However, these techniques have been designed to
quantify the effect of a single intervention. In trying to apply
these techniques to our problem of finding optimal treatment
for patients suffering from varying sets of diseases, we face
two challenges.
First, patients with multiple conditions will likely need
a combination of drugs. Quantifying the effect of multi-
ple concurrent interventions is semantically different from
considering only a single intervention. The key concept in
estimating the effect of an intervention is comparability : to
estimate the effect of intervention, we need two groups of
patients who are identical in all relevant aspects except that
one group receives the intervention and the other group does
not. For a single intervention, the first group is typically the
sickest patients who still do not get treated and the second
group consists of the healthiest patient who get treatment.
They are reasonably in the same state of health. However,
when we go from a single intervention to multiple interven-
tion and try to estimate their joint effect, comparability no
longer exists. A patient requiring multiple simultaneous in-
terventions is so fundamentally different from a patient who
does not need any intervention that they are not compara-
ble.
The other key challenge in finding optimal intervention
sets for patients with combinatorial sets of diseases is the
combinatorial search space. Even if we could trivially extend
the methods for quantifying the effect of a single interven-
tion to a set of concurrent interventions, we would have to
systematically explore a combinatorially large search space.
The association rule mining framework [2] provides an ef-
ficient solution for exploring combinatorial search spaces,
however, it only detects associative relationships. Our in-
terest is in causal relationships.
In this manuscript, we propose causal rule mining, a frame-
work for transitioning from association rule mining towards
causal inference in subpopulations. Specifically, given a set
of interventions and a set of items to define subpopulations,
we wish to find all subpopulations in which effective inter-
vention combinations exist and in each such subpopulation,
we wish to find all intervention combinations such that drop-
ping any intervention from this combination will reduce the
efficacy of the treatment. We call these closed intervention
sets, which are not be confused with closed item sets. As
a concrete example, interventions can be drugs, subpopula-
tions can be defined in terms of their diseases and for each
subpopulations (set of diseases), our algorithm would return
effective drug cocktails of increasing number of constituent
drugs. Leaving out any drug from the cocktail will reduce
the efficacy of the treatment. Closed intervention sets allow
us to go from estimating a single intervention to multiple
interventions.
To address the exploration of the combinatorial search
space, we propose a novel frequency-based anti monotonic
pruning strategy enable by the closed intervention set con-
cept. The essence of antimonotonic property is that if a set
I of interventions does not satisfy a criterion, none of its
supersets will. The proposed pruning strategy based on the
closed intervention is strictly more efficient than the tradi-
tional pruning strategy used by the Apriori algorithm [2].
Underneath our combinatorial exploration algorithm, we
utilize the Rubin-Neyman model of causation [3]. This model
sets two conditions for causation: a set X of interventions
causes a change in Y iff X happens before Y and Y would be
different had X not occurred. The unobservable outcome of
what would happen had a treated patient not received treat-
ment is a potential outcome and needs to be estimated. We
present and compare five methods for estimating these po-
tential outcomes and describe the biases these methods can
correct.
Typically the ground truth for the effect of drugs is not
known. In order to assess the quality of the estimates, we
conduct a simulation study utilizing five different synthetic
data set that introduce a new source of bias. We will eval-
uate the effect of the bias on the five proposed methods
underscoring the statements with rigorous proofs when pos-
sible.
We also evaluate our work on a real clinical data set from
Mayo Clinic. We have data for over 52,000 patients with 13
years of follow-up time. Our outcome of interest is 5-year
incident T2DM and we wish to extract patterns of interven-
tions for patients suffering from combinations of common
comorbidities of T2DM. First, we evaluate our methodology
in terms of the computational cost, demonstrating the effec-
tiveness of the pruning methodologies. Next, we evaluate the
patterns qualitatively, using patterns involving statins. We
show that our methodology extracted patterns that allow us
to explain the controversial patterns surrounding statin [4].
Contributions. (1) We propose a novel framework for ex-
tracting causal rules from observational data correcting for a
number of common biases. (2) We introduce the concept of
closed intervention sets to extend the concept of quantifying
the effect of a single intervention to a set of concurrent in-
terventions sidestepping the patient comparability problem.
Closed intervention sets also allow for a pruning strategy
that is strictly more efficient than the traditional pruning
strategy used by the Apriori algorithm [2]. (3) We compare
five methods of estimating causal effect from observational
data that are applicable to our problem and rigorously eval-
uate them on synthetic data to mathematically prove (when
possible) why they work.
4.2 Background: Association Rule Mining
We first briefly review the fundamental concepts of asso-
ciation rule mining and extend these concepts to causal rule
mining in the next section. Consider a set I of items, which
are single-term predicates evaluating to ‘true’ or ‘false’. For
example, {age > 55} can be in item. A k-itemset is a set
of k items, evaluated as the conjunction (logical ’and’) of
its constituent items. Consider a dataset D = { d1, d2.....dn
}, which consists of n observations. Each observation, de-
noted by Dj is a set of items. An itemset I = i1, i2, . . . , ik
(I ⊂ I) supports an observation Dj if all items in I eval-
uate to ‘true’ in the observation. The support of I is the
fraction of the observations in D that support I. An item-
set is frequent if its support exceeds a pre-defined minimum
support threshold.
A association rule is a logical implication of form X ⇒ Y ,
where X and Y are disjoint itemsets. The support of a rule
is support(XY ) and the confidence of the rule is
conf(X ⇒ Y ) = support(XY )
support(X)
= P(Y |X).
4.2.1 Causal Rule Mining
Given an intervention itemset X and an outcome item
Y , such that X and Y are disjoint, a causal rule is an impli-
cation of form X → Y , suggesting that X causes a change
in Y . Let the itemset S define a subpopulation, consist-
ing of all observations that support S. This subpopulation
consists of all observations for which all items in S evalu-
ate to ‘true’. The causal rule X → Y |S implies that the
intervention X has causal effect on Y in the subpopulation
defined by S. The quantity of interest is the causal effect,
which is the change in Y in the subpopulation S caused by
X. We will formally define the metric used to quantify the
causal effect shortly.
Rubin-Neyman Causal Model. X has a causal effect
on Y if (i) X happens earlier than Y and (ii) if X had not
happened, Y would be different [3].
Our study design ensures that the intervention X precedes
the outcome Y , but fulfilling the second conditions requires
that we estimate the outcome for the same patient both
under intervention and without intervention.
Potential Outcomes. Every patient in the dataset has two
potential outcomes: Y0 denotes their outcome had they not
had the intervention X; and Y1 denotes the outcome had
they had the intervention. Typically, only one of the two po-
tential outcomes can be observed. The observable outcome
is the actual outcome (denoted by Y ) and the unobservable
potential outcome is called the counterfactual outcome.
Using the definition of counterfactual outcome, we can
now define the metric for estimating the change in Y caused
by X. Average Treatment response on the Treated
(ATT) is a widely known metric in the causal literature and
is computed as follows:
ATT(X → Y |S) = E[Y1 − Y0]X=1 = E[Y1]X=1 − E[Y0]X=1,
where E denotes the expectation and the X = 1 in the sub-
script signals that we only evaluate the expectation in the
treated patients (X = 1).
ATT aims to compute an average per-patient change caused
by the intervention. Y0 = Y1, indicates that the intervention
resulted in no change in outcome for the patient.
Biases. Beside X, numerous other variables can also exert
influence over Y , leading to biases in the estimates. To
correct for these biases, we have correctly account for these
other effects. The quintessential tool for this purpose is the
causal graph, depicted in Figure 4. The nodes of this graph
are sets of variables that play a causal role and edges are
causal effects. This is not a correlation graph (or dependence
graph), because for example, U and Z are dependent given
X, yet there is no edge between them.
Variables (items in I) can exert influence on the effect of
X on Y in three way: they may only influence X, they may
only influence Y or them may influence both X and Y . Ac-
cordingly, variables can be categorized into four categories:
V are variables that directly influence Y and thus have
direct effect on Y
U are variables that only influence Y through X and
thus have indirect effect on Y ;
Z are variables that influence both X and Y and are
called confounders; and finally
O are variables that do not influence either X or Y
and hence can be safely ignored.
Figure 4: Rubin-Neyman Causal Model
Most of the causal inference literature assumes that the
causal graph is known and true. In other words, we know
apriori which variables fall into each of the categories, U ,
Z, V and O. In our case, only X and Y are specified and
we have to infer which category each other variable (item)
belongs to. Since this inference relies on association (de-
pendence) rather than causation, the discovered graph may
have errors, misclassifications of variables into the wrong
category. For example, because of the marginal dependence
between U and Y , variables in U can easily get misclassi-
fied as Z. Such misclassifications do not necessarily lead to
biases, but they can cause loss of efficiency.
Problem Formulation. Given a data set D, a set S of
subpopulation-defining items, a set X of intervention
items, a minimal support threshold θ and a minimum effect
threshold η, we wish to find all subpopulations S (S ⊂ S)
and all intervetions X (X ⊂ X ), X and S are disjoint, such
that the causal rule X → Y |S is frequent and its intervention
set X is closed w.r.t. our metric of causal effect, ATT.
Note that the meaning of θ, the minimum support thresh-
old, is different than in association rule mining literature.
Typically, rules with support less than θ are considered un-
interesting, in other cases, it is simply a computational con-
venience, but in our case, we set θ to a minimum value such
that ATT is estimable for the discovered patterns.
We call a causal rule frequent iff its support exceeds the
user-specified minimum threshold θ
support(X → Y |S) = support(XY S) = P(XY S) > θ
and we call an intervention set X closed w.r.t. to ATT iff
∀x ∈ X, |ATT (x→ Y |S,X\x)| > η,
where η is the user-specified minimum causal effect thresh-
old. In other words, a causal rule is closed in a subpopu-
lation, if its (absolute) effect is greater than any of its sub-
rules.
Example. In a medical setting, X may be drugs, S could
be comorbid diseases. Then X is a drug-combination that
hopefully treats set of diseases S. This set of drugs being
closed w.r.t. ATT means that dropping any drug from X
will reduce the overall efficacy of the treatment; the patient
is not taking unnecessary drugs.
An itemset is closed if its support is strictly higher than
all of its subitemsets’. Analogously, an intervention set is
closed if its absolute causal effect is strictly higher than all
of its subitemsets’.
4.2.2 Frequent Causal Pattern Mining Algorithm
We can now present our algorithm for causal pattern min-
ing. At a very high level, the algorithm comprises of two
nested frequent pattern enumeration [30] loops. The outer
loop enumerates subpopulation-defining itemsets S using
items in S, while the inner loop enumerates intervention
combinations using items in X \ S. More generally, X and
S can overlap but we do not consider that in this paper. Ef-
fective algorithms to this end exists [31, 32], we simply use
Apriori [2].
Once the patterns are discovered, the ATT of the interven-
tions are computed, using one of the methods from Section
4.3 and the frequent, effective patterns are returned.
On the surface, this approach appears very expensive,
however several novel, extremely effective pruning strategies
are possible and we describe them below.
Potential Outcome Support Pruning. Let X be an
intervention k-itemset, S be a subpopulation-defining item-
set, and let X and S be disjoint. Further, X−i be an itemset
that evaluates to ‘true’ iff all items except the ith are ‘true’
but the ith item is ‘false’. Using association rule mining ter-
minology, all items in X except the ith are present in the
transaction.
Definition 1 (Potential Outcome Support Pruning).
We only need to consider itemsets X such that
min{support(S,X), support({S,X−1), . . . ,
support(S,X−k)} > θ.
In order to be able to estimate the effect of x ∈ X in the
subpopulation S, we need to have observations with x ‘true’
and also with x ‘false’ in S.
Lemma 1. Potential Outcome Support Pruning is anti-
monotonic.
Proof: Consider a causal rule X → Y |S . If the causal rule
X → Y |S is infrequent, then
support(XS) < θ ∨ ∃i, support(X−iS) < θ.
If support(X−iS) had insufficient support, then any exten-
sion of it with an intervention item x will continue to have
insufficient support, thus the Xx → Y |S rule will have in-
sufficient support. Likewise, if support(XS) had insufficient
support, then any extension of it with an intervention item
x will also have insufficient support.
Pruning based on Causal Effect.
Proposition 1. Effective causal rule pruning condition
is anti-monotonic.
Rationale: To explain the rational, let us return to the
medical example, where X is a combination of drugs forming
a treatment. Assuming that the effects of drugs are additive,
if a casual rule X → Y |S is ineffective because
∃xi ∈ X, |ATT(xi → Y |S,X\xi)| < η,
then forming a new rule Xxj → Y |S will also be ineffective
because
|ATT(xi → Y |S,xj ,X\xi)|
will be ineffective. In the presence of positive interactions
(that reinforce each other’s effect) among the drugs, this
statement may not hold true. Beside statistical reasoning,
one can question why a patient should receive a drug that
has no effect in a combination.
4.3 Causal Estimation Methods
ATT, our metric of interest, with respect to a single in-
tervention x in a subpopulation S is defined as
ATT(x→ Y |S) = E [Y1 − Y0]S,X=1 ,
which is the expected difference between the potential out-
come under treatment Y1 and the potential outcome with-
out treatment Y0 in patients with S who actually received
treatment. Since we consider treated patients, the potential
outcome Y1 can be observed, the potential outcome Y0 can-
not. Thus at least one of the two must be estimated. The
methods we present below differ in which potential outcome
they estimate and how they estimate it.
For the discussion below, we consider the variables X, Z,
U and V from the causal graph in Figure 4. X is a single
intervention, U , V and Z can be sets of items. For regression
models, we will denote the matrix defined by U , V and Z
in the subpopulation S as U , V and Z (same letter as the
variable sets).
Counterfactual Confidence (CC). This is the simplest
method. We simply assume that the patients who receive
intervention X = 1 and those who do not X = 0, do not dif-
fer in any important respect that would influence Y . Under
this assumption, Y1 in the treated is simply the actual out-
come in the treated and the potential outcome Y0 is simply
the actual outcome in the non-treated (X = 0). Thus
ATT = conf((X = 1)→ Y |S)− conf((X = 0)→ Y |S),
= P(Y |S,X = 1)− P(Y |S,X = 0)
In the followings, to improve readability, we drop the S
subscript. All evaluations take place in the S subpopula-
tions.
Direct Adjustment (DA). We cannot estimate Y0 in the
treated (X = 1) as the actual outcome Y in the untreated,
because the treated and untreated populations can signifi-
cantly differ in variables such as Z and V that influence Y .
In Direct Adjustment, we attempt to directly remove the ef-
fect of V and Z by including them into a regression model.
Since a regression model relates the means of the predictors
with the mean of the outcome, we can remove the effect of
V and Z by making their means 0.
Let R be a generalized linear regression model, predicting
Y via a link function g
g(Y |V,Z,X) = β0 + βV V + βZZ + βXX.
Then the (link-transformed) potential outcome under treat-
ment is g(Y1) = β0 + βV V + βZZ + βX and the potential
outcome without treatment is g(Y0) = β0 + βV V + βZZ.
The ATT is then
ATT = E
[
g−1(Y1|V,Z,X = 1)
]
X=1
−
E
[
g−1(Y0|V,Z,X = 0)
]
X=1
.
where g−1(Y1|V,Z,X = 1) is prediction for an observation
with the observed V and Z but with X set to 1. The E(·)X=1
notation signifies that these expectation of the predictions
are taken only over patients who actually received the treat-
ment.
The advantage of DA (over CC) is manyfold. First, it can
adjust for Z and V as long the model specification is correct,
namely the interaction terms that may exist among Z and V
are specified correctly. Second, we get correct estimates even
if we ignore U , because U is conditionally independent of Y
given X. This unfortunately only is a theoretical advantage,
because we have to infer from the data whether a variable
is a predictor of Y and U is marginally dependent on Y , so
we will likely adjust for U , even if we don’t need to.
Counterfactual Model (CM). In this technique, we build
an explicit model for the potential outcome without treat-
ment Y0 using patients with X = 0. Specifically, we build a
model
g(Y |V,Z,X = 0) = β0 + βV V + βZZ.
and estimate the potential outcome as
g(Y0|V,Z) = g(Y |V,Z,X = 0).
The ATT is then
ATT = P(Y |X = 1)− E [g−1(Y0|V,Z)]X=1 .
Similarly to Direct Adjustment, the Counterfactual Model
does not depend on U . However, in case of the Counterfac-
tual Model, we are only considering the population with
X = 0. In this population, U and Y are independent, thus
we will not include U variables into the model.
Propensity Score Matching (PSM). The central idea
of Propensity Score Matching is to create a new population,
such that patients in this new population are comparable in
all relevant respects and thus the expectation of the poten-
tial outcome in the untreated equals the expectation of the
actual outcome in the untreated.
Patients are matched based on their propensity of receiv-
ing treatment. This propensity is computed as a logistic
regression model with treatment as the dependent variable
log
P(X)
1− P(X) = β0 + βV V + βZZ.
Patient pairs are formed, such that in each pair, one patient
received treatment and the other did not and their propen-
sities for treatment differ by no more than a user-defined
caliper difference ρ.
The matched population has an equal number of treated
and untreated patients, is balanced on V and Z, thus the
patients are comparable in terms of their baseline risk of Y .
Hopefully, the only factor causing a difference in outcome is
the treatment.
For estimating ATT, the potential outcome without treat-
ment is estimated from the actual outcomes of the patients
in the matched population who did not receive treatment:
ATT = E [Y1 − Y0]
− P(Y |X = 1,M)− P(Y |X = 0,M),
where M denotes the matched population.
Among the methods we consider, propensity score match-
ing most strictly enforces the patient comparability crite-
rion, however, it is susceptible to misspecification of the
propensity regression model, which can erode the quality
of the matching.
Stratified Non-Parametric (SN). In the stratified esti-
mation, we directly compute the expectation via stratifica-
tion. The assumption is that the patient in each stratum
are comparable in all relevant respects and only differ in the
presence or absence of intervention. In each stratum, we
can estimate the potential outcome Y0 in the treated as the
actual outcome Y in the untreated.
ATT = E [Y1 − Y0]X=1
=
∑
l
P (l|X = 1) [P (Y1|l,X = 1)− P (Y0|l,X = 1)]
=
∑
l
P (l|X = 1) [P (Y |X = 1)− P (Y |X = 0)] ,
where l iterates over the combined levels of V and Z. If we
can identify the items that fall into U , then we can ignore
them, otherwise, we should include them as well into the
stratification.
The stratified method makes very few assumptions and
should arrive at the correct estimate as long as each of the
strata are sufficiently large. The key disadvantage of the
stratified method lies in stratification itself: when the num-
ber of items across which we need to stratify is too large, we
may end up dividing the population into excessively many
small subpopulations (strata) and become unable to esti-
mate the causal effect in many of them thus introducing
bias into the estimate.
4.4 Results
After describing our data and study design, we present
three evaluations of the proposed methodology. The first
evaluation demonstrates the computational efficiency of our
pruning methodologies, isolating the effect of each prun-
ing methods: (i) Apriori support-based pruning, (ii) Po-
tential Outcome Support Pruning, and (iii) Potential Out-
come Support Pruning in conjunction with Effective Causal
Rule Pruning. In the second section, we provide a quali-
tative evaluation, looking at patterns involving statin. We
attempt to use the extracted patterns to explain the con-
troversial findings that exist in the literature regarding the
effect of statin on diabetes. Finally, in order to compare the
treatment effect estimates to a ground truth, which does not
exits for real drugs, we simulate a data set using proportions
we derived from the Mayo Clinic data set.
Data and Study Design. In this study we utilized a
large cohort of Mayo Clinic patients with data between 1999
and 2013. We included all adult patients (69,747) with re-
search consent. The baseline of our study was set at Jan. 1,
2005. We collected lab results, medications, vital signs and
status, and medication orders during a 6-year retrospective
period between 1999 and the baseline to ascertain the pa-
tient’s baseline comorbidities. From this cohort, we excluded
all patients with a diagnosis of diabetes before the baseline
(478 patients), missing fasting plasma glucose measurements
(14,559 patients), patients whose lipid health could not be
determined (1,023 patients) and patients with unknown hy-
pertension status (498 patients). Our final study cohort con-
sists of 52,139 patients who were followed until the summer
of 2013.
Patients were phenotyped during the retrospective period.
Comorbidities of interest include Impaired Fasting Glucose
(IFG), abdominal obesity, Hypertension (HTN; high blood
pressure) and hyperlipidemia (HLP; high cholesterol). For
each comorbidity, the phenotyping algorithm classified pa-
tients into three broad levels of severity: normal, mild and
severe. Normal patients show no sign of disease; mild pa-
tients are either untreated and out of control or are con-
trolled using first-line therapy; severe patients require more
aggressive therapy. IFG is categorized into normal and pre-
diabetic, the latter indicating impaired fasting plasma glu-
cose levels but not meeting the diabetes criteria yet. For
this study, progression to T2DM within 5 years from base-
line (i.e. Jan 1, 2005) was chosen as our outcome of interest.
Out of 52,139 patients 3627 patients progressed to T2DM ,
41028 patients did not progressed to T2DM and the remain-
ing patients (7484) dropped out of the study. In Table 2 we
present statistics about our patient population.
4.4.1 Pruning Efficiency
In our work, we proposed two new pruning methods. First,
we have the Potential Outcome Support Pruning, which
aims to eliminate patterns for which the ATT is not es-
timable. Second, we have the Effective Causal Rule Pruning,
where we eliminate patterns that do not improve treatment
effectiveness relative to the subitemsets.
In Figure 5 we present the number of patterns discovered
using (i) the traditional Apriori support based pruning, (ii)
our proposed Potential Outcome Support Pruning (POSP),
and (iii) POSP in conjunction with Effective Causal Rule
Pruning (ECRP).
The number of patterns discovered by POSP is strictly
less than the number of patterns discovered by the Apriori
pruning. POSP in conjunction with ECRP is very effective.
4.4.2 Statin
In this section, we demonstrate that the proposed causal
rule mining methodology can be used to discover non-trivial
patterns from the above diabetes data set.
In recent years, the use of statins, a class of cholesterol-
lowering agents, have been prescribed increasingly. High
cholesterol (hyperlipidemia) is linked to cardio-vascular mor-
tality and the efficacy of statins in reducing cardio-vascular
mortality is well documented. However, as evidenced by a
2013 BMJ editorial [4] devoted to this topic, statins are sur-
T2DM
Present Absent
Total Number of Patients 3627 41028
Average Age 44.73 35.58
Male(%) 51 41
Female(%) 49 59
Patient Diagnosis Status (%)
NormFG 42 84
PreDM 58 16
Normal Obesity 29 59
Mild Obesity 25 30
Severe Obesity 46 11
Normal Hypertension 48 69
Mild Hypertension 33 23
Severe Hypertension 19 08
Normal Hyperlipidemia 12 29
Mild Hyperlipidemia 72 64
Severe Hyperlipidemia 16 07
Patient Medication Status(%)
Statin 26 11
Fibrates 03 01
Cholesterol.Other 02 01
Acerab 17 07
Diuret 18 07
CCB 08 04
BetaBlockers 22 10
HTN.Others 01 01
Table 2: Demographics statistics of patient popula-
tion
Figure 5: Comparison of Pruning Techniques
rounded in controversy. In patients with normal blood sugar
levels (labeled as NormalFG), statins have a detrimental ef-
fect, they increase the risk of diabetes; yet in pre-diabetic
patients (PreDM), it appears to have no effect. What we
demonstrate below is that this phenomenon is simply dis-
ease heterogeneity.
First, we describe how this problem maps to the causal
rule mining problem. Our set of interventions (X ) consists
of statin and our subpopulation defining variables consist of
the various levels of HTN, HLP and IFG (S). Our inter-
est is the effect of statin (x) on T2DM (Y ) in all possible
subpopulations S, S ⊂ S.
In this setup, HTN, which is associated with both hy-
perlipidemia (and statin use), as well as with T2DM, is
a confounder (Z). A cholesterol drug, other than statin,
(say) fibrates, are in the U category: they are predictive of
statin (patients on monotherapy who take fibrates do not
take statins), but have no effect on Y , because its effect is
already incorporated into the hyperlipidemia severity vari-
ables that defined the subpopulation. Variables that only
influence diabetes but not statin use (say a diabetes drug)
would fall into the V category. All subpopulations have vari-
ables that fall into Z and U and some subpopulation may
also have V .
The HLP variable in Table 2 uses statin as part of its defi-
nition, thus we constructed two new variables. The first one
is HLP1, a variable at the borderline between HLP-Normal
and HLP-Mild, consisting of untreated patients with mildly
abnormal lab results (these fall into HLP-Normal) and pa-
tients who are diagnosed and receive a first-line treatment
(they fall into HLP-Mild). Comparability is the central con-
cept of estimating causal effects and these patients are com-
parable at baseline. Similarly, we also created another vari-
able, HLP2, which is at the border of HLP-Mild and HLP-
Severe, again consisting of patients who are comparable in
relevant aspects of their health at baseline.
S CC DA CM PSM SN
PreDM 0.145 0.022 0.010 0.022 0.017
NormFG 0.060 0.023 0.034 0.017 0.029
HLP1 0.078 0.019 0.014 0.010 0.010
HLP2 0.021 -0.013 -0.010 -0.021 -0.015
PreDM,HLP1 0.067 0.018 0.021 0.004 0.002
PreDM,HLP2 0.001 -0.038 -0.031 -0.048 -0.043
NormFG,HLP1 0.043 0.020 0.015 0.014 0.013
NormFG,HLP2 0.017 -0.002 -0.002 -0.005 -0.004
Table 3: ATT due to statin in various subpopula-
tions S as estimated by the 5 proposed methods.
Table 3 presents the ATT estimates obtained by the var-
ious methods proposed in Section 3.4 for some of the most
relevant subpopulations. Negative ATT indicates beneficial
effect and positive ATT indicates detrimental effect.
Counterfactual confidence (CC) estimates statin to be detri-
mental in all subpopulations. While statins are known to
have detrimental effect in patients with normal glucose lev-
els [4], it is unlikely that statins are universally detrimental,
even in patients with severe hyperlipidemia, the very disease
it is supposed to treat.
The results between DA, CM, PSM and SN are similar,
with PSM and SN having larger effect sizes in general. The
picture that emerges from these results is that patients with
severe hyperlipidemia appear to benefit from statin treat-
ment even in terms of their diabetes outcomes, while statin
treatment is moderately detrimental for patients with mild
hyperlipidemia.
Bootstrap estimation was used to compute the statisti-
cal significance of these results. For brevity, we report the
results only for PSM. The estimates are significant in the fol-
lowing subpopulations: NormFG, PreDM+HLP2 (p-values
are <.001) and NormFG+HLP1 (p-value .05).
The true ATT in these subpopulations is not know. To
investigate the accuracy that the various methods achieve,
we use simulated that is largely based on this example [4,
33].
4.4.3 Synthetic Data
In this section, we describe four experiments utilizing syn-
thetic data sets, each of which introduces a new potential
source of bias. Our objective is to illustrate the ability of the
five methods from Section 3.4 for adjusting for these biases.
We compare their ATT estimates to the true ATT we used
to generate the data set and discuss reasons for their success
or failure.
The rows of Table 4 correspond to the synthetic data sets in
increasing order of the biases we introduced and the columns
corresponds to the methods: Conf (confidence), CC (Coun-
terfactual Confidence), DA (Direct Adjustment), CM (Coun-
terfactual Model), PSM (Propensity Score Matching) and
SNP (Stratified Non-Parametric).
Some of these methods, DA, CM, PSM and SNP take the
causal graph structure into account while estimating ATT.
Specifically, they require the information whether a variable
is a confounder (Z), has a direct effect (V ), an indirect effect
(V ), or no effect (O). PSM and SNP are not sensitive to the
inclusion of superfluous variables, they simply decrease the
method’s efficiency.
In all of the data sets, we use a notation consistent with
Figure 1: Z is the central disease with outcome Y ; X is the
intervention of interest that treats Z; V is another disease
with direct causal effect on Y , but V is independent of X;
and U is a third disease, which can be treated with X, but
has no impact on Y . All data sets contain 5000 observations.
I. Direct Causal Effect from V . We assume that every pa-
tient in the cohort has disease Z at the same severity. They
are all comparable w.r.t. Z. 30% of the patients are sub-
ject to the intervention X aimed at treating Z, while others
are not. Untreated patients face a 25% chance of having Y ,
while treated patients only have 10% chance. Some patients,
20% of the population, also have disease V , which directly
affects Y : it increases the probability of Y by 5%.
In this example the true ATT is -.15, as X reduces the
chance of Y by 15%. Our causal graph dictates that X
and V be marginally independent, hence this this effect is
homogeneous across the levels of V . (Otherwise V would
become predictive of X and it would become a confounder.
Confounding is discussed in experiments III-V.) All methods
estimated the ATT correctly, because ATT does not depend
on V . We can demonstrate this by stratifying on V and
using the marginal independence of X and V .
ATT = E [P(Y |X = 1)− P(Y |X = 0)]
=
∑
v∈V
P(V = v) [P(Y |V = v,X = 1)− P(Y |V = v,X = 0)]
=
∑
v∈V
[P(Y, V = v|X = 1)− P(Y, V = v|X = 0)]
= P(Y |X = 1)− P(Y |X = 0)
where v denotes the levels of V . The marginal independence
of X and V is used in step three:
P(Y |V,X) = P(Y, V,X)
P(V,X)
=
P(Y, V |X)P(X)
P(X,V )
=
P(Y, V |X)
P(V )
.
II. Indirect Causal Effect. The setup for this experiment is
the same as for the ’Direct Causal Effect’ experiment, except
we have disease U instead of V . Just like Z, disease U is
also treated by X, but U has no direct effect on Y ; its effect
is indirect through X. U is thus independent of Y given X.
The true ATT continues to be -.15.
Again, the ATT does not depend on U , hence all methods
estimated it correctly. To demonstrate that ATT does not
depend on U , we use stratification and the conditional inde-
pendence of Y and U .
ATT = E [P(Y |X = 1)− P(Y |X = 0)]
=
∑
u∈U
[P(Y |U = u,X = 1)P(U = u|X = 1)
−P(Y |U = u,X = 0)P(U = u|X = 0)]
=
∑
u∈U
[P(Y |X = 1)P(U = u|X = 1)
−P(Y |X = 0)P(U = u|X = 0)]
= P(Y |X = 1)
∑
u
P(U = u|X = 1)−
P(Y |X = 0)
∑
u
P(U = u|X = 0)
= P(Y |X = 1)− P(Y |X = 0)
III. Confounding. In this experiment, we consider the sim-
plest case of confounding, involving a single disease Z, a
single treatment X and outcome Y . 20% of the patients
have disease Z and 95% of the diseased patients are treated
with X, while 5% are not. All treated patients have Z. 25%
of the untreated patients (Z = 1 and X = 0) have outcome
Y ; 10% of the treated patients (Z = 1 and X = 1) have the
outcome; and only 5% of the healthy patients (Z = 0) have
it. The true ATT is -.15.
In the presence of confounding, the counterfactual confi-
dence and ATT do not coincide. With z denoting the levels
of Z and P(z) being a shorthand for P(Z = z),
ATT = E [P(Y |X = 1)− P(Y |X = 0)]
=
∑
z
P(z) [P(Y |X = 1, z)− P(Y |X = 0, z)] ,
while the counterfactual confidence (CC) is
CC = P(Y |X = 1)− P(Y |X = 0)
=
∑
z
[P(Y |X = 1, z)P(z|X = 1)
−P(Y |X = 0, z)P(z|X = 0)] .
When P(z|X) 6= P(z), these quantities do not coincide.
However, any method that can estimate P(Y |X,Z) for all
levels of Z and X will arrive at the correct ATT estimate.
We used logistic regression in our implementation of the
Direct Adjustment method, which can estimate P(Y |X,Z)
when X and Z have no interactions. Note that the causal
graph admits interaction between X and Z, thus model mis-
specification can cause biases in the estimate.
IV. Confounding with Indirect Effect. In addition to the
Confounding experiment, we also have an indirect causal
effect from U . We now have two diseases, Z and U , each
of which can be treated with X. 20% of the population has
Z and independently, 20% has U . 25% of the patients who
have Z and have no treatment (X = 0) have Y , while only
10% of the treated (X = 1) patients have it, regardless of
whether the patient has U . (If the probability of Y was
affected by U , it would be another confounder, rather than
have an indirect effect.)
X has a beneficial ATT of -.15 in patients with Z == 1 (and
X == 1) and has no effect in patients with Z = 0 (who get
X because of U). Thus the true ATT=-.0833.
In this experiment, the counterfactual model was the best-
performing model. The counterfactual model estimates the
ATT through the definition
ATT = E [P(Y1|X = 1)− P(Y0|X = 1)] ,
where Y0 is the potential outcome the patient would have
without treatment X = 0 and P(Y0|X = 1) is the coun-
terfactual probability of Y (the probability of Y had they
not received X) in the population who actually got X = 1.
Note that the potential outcome Y1|X = 1 in the patients
who actually got X = 1 is the observed outcome Y |X = 1.
With u and z denoting the levels of U and Z, respectively
and P(u) being a shorthand for P(U = u),
ATT = E [P(Y |X = 1)− P(Y0|X = 1)]
=
∑
u
∑
z
P(u, z) [P(Y |X = 1, u, z)− P(Y0|X = 1, u, z)]
=
∑
z
P(z)
∑
[P(Y |X = 1, z)− P(Y0|X = 1, z)]
=
∑
z
P(z)
∑
[P(Y |X = 1, z)− P(Y |X = 0, z)] ,
which coincides with the data generation mechanism, hence
the estimate is correct.
In the derivation, step 2 holds because U and Z are inde-
pendent givenX and step 3 uses the fact that the counterfac-
tual model estimates P0(Y |X = 1, z, u) from the untreated
patients, thus
P(Y0|X = 1, z, u) = P(Y |X = 0, z, u) = P(Y |X = 0, z).
V. Confounding with Direct and Indirect Effects. In this ex-
periment, we have three diseases: our index disease Z, which
is a confounder; U having an indirect effect on Y via X; and
V having a direct effect on Y . 20% of the population has
each of Z, V and U independently. 95% of patients with Z
or U get the intervention X. 25% of the untreated patients
with Z get Y , while only 10% of the treated patients do,
regardless of whether they have U . Patients with V face a
5% in their chance of experiencing outcome Y .
X has a beneficial ATT of -.15 in patients with Z = 1 and
have no effect in patients with Z = 0 (who get X because of
U). Whether a patient has V does not influence the effect
of X. The true ATT is thus -.0833.
None of the methods estimated the effect correctly, but Propen-
sity Score Matching came closest. Analytic derivation of
why it performed well is outside the scope of this paper, but
in essence, its success is driven by its ability to maximally ex-
ploit the independence relationships encoded in the causal
graph. It can ignore V when it constructs the propensity
score model, because X and V are independent (when Y
not given); and it can ignore U and V when it computes the
ATT in the propensity matched population. On the other
hand, the causal graph admits interaction among U , Z and
X, thus a logistic regression model as the propensity score
model can be subject to model misspecification.
The Stratified Non-Parametric method, which is essentially
just a direct implementation of the definition of ATT, un-
derestimated the ATT by almost 25%. The reason lies in the
excessive stratification across all combinations of the levels
of U , V , and Z. Even with just three variables, most strata
did not have sufficiently many patients (either treated or
untreated) to estimate P(Y |X,u, v, z). In the discussion, we
will describe remedies to overcome this problem.
Conf CC DA CM PSM SN
I. +.110 -.150 -.150 -.150 NA -.150
II. +.099 -.150 -.150 -.150 -.151 -.149
III. +.099 +.047 -.136 -.136 -.136 -.136
IV. +.077 +.024 -.019 -.083 -.068 -.064
V. +.072 +.038 -.037 -.105 -.074 -.067
Table 4: The ATT estimates by the 6 methods in the
five experiments. The experimental conditions, the
full names of the methods and the true ATT value
are specified in the text.
5. DISCUSSION AND CONCLUSION
We proposed the causal rule mining framework, which
transitions pattern mining from finding patterns that are
associated with an outcome towards patterns that cause
changes in the outcome. Finding causal relationships in-
stead of associations is absolutely critical in health care, but
also has appeal beyond health care.
The numerous biases that arise in establishing causation
make quantifying causal effects difficult. We use the Neyman-
Rubin causal model to define causation and use the poten-
tial outcome framework to estimate the causal effects. We
correct for three kinds of potential biases: those stemming
from direct causal effect, indirect causal effect and confound-
ing. We compared five different methods for estimating the
causal effect, evaluated them on real and synthetic data and
found that three of these methods gave very similar results.
We have demonstrated on real clinical data that our pro-
posed method can effectively enumerate causal patterns in a
large combinatorial search space due to the two new pruning
methods we developed for this work. We also demonstrated
that the patterns discovered from the data were very rich
and we managed to illustrate how the effect of statin is dif-
ferent in various subpopulations. The results we found are
consistent with the literature but go beyond what is already
known about statin’s effect on the risk of diabetes.
The discussions and experimental results provided in this
paper provide some general guidance on when to use the
different methods we described. We recommend counterfac-
tual confidence if no confounding is suspected as counterfac-
tual confidence is computationally efficient and can arrive
at the correct solution even when direct effects and indirect
effects are present. In the presence of confounding, propen-
sity score matching gave the most accurate results, but due
to the need to create a matched population, it has built-in
randomness, increasing its variance. Moreover, the counter-
factual model as well as the propensity score model are sus-
ceptible to model misspecification. If unknown interactions
among variables are suspected, we recommend the strati-
fied non-parametric method. With this technique, model
misspecification is virtually impossible, however, its sample
size requirement is high. The stratified model is subopti-
mal if we need to stratify across many variables. Stratify-
ing across many variables can fragment the population into
many strata too small to afford us with the ability to esti-
mate the effects correctly. If the estimates use some strata
but not others, they may be biased.
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